Entero Healthcare Solutions Ltd
NSE:ENTERO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Entero Healthcare Solutions Ltd
NSE:ENTERO
|
IN |
|
Liberty Media Corp
NASDAQ:FWONA
|
US |
|
G M Breweries Ltd
NSE:GMBREW
|
IN |
|
Soluna Holdings Inc
NASDAQ:SLNH
|
US |
|
A
|
Awardit AB publ
STO:AWRD
|
SE |
|
Methanor SCA
PAR:ALMET
|
FR |
|
Kerry Logistics Network Ltd
HKEX:636
|
HK |
|
Express Transindo Utama Tbk PT
IDX:TAXI
|
ID |
|
China Merchants Property Operation & Service Co Ltd
SZSE:001914
|
CN |
|
Stockwik Forvaltning AB
STO:STWK
|
SE |
|
P
|
Peugeot Invest SA
LSE:0HV8
|
FR |
|
Spencer's Retail Ltd
NSE:SPENCERS
|
IN |
|
Beijing Strong Biotechnologies Inc
SZSE:300406
|
CN |
|
Celyad Oncology SA
XBRU:CYAD
|
BE |
|
B
|
Beijing Succeeder Technology Inc
SSE:688338
|
CN |
|
BAIC Motor Corp Ltd
HKEX:1958
|
CN |
|
G-Next Inc
TSE:4179
|
JP |
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd is a IN-based company operating in Health Care Providers & Services industry. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2024-02-16. Entero Healthcare Solutions Limited is an India-based technology-driven and integrated healthcare products distribution company. The company offers a range of pharmaceuticals and other healthcare products to approximately 81,400 retail pharmacies and healthcare practitioners. Its portfolio includes 64500+ SKUs from approximately 1900 pharma companies. The company is a supplier for approximately 3,400 hospitals across India, including corporate hospital chains. The company sells private label products under its private label, Entero Surgicals. The company offers both demand generation and demand fulfilment solutions to healthcare product manufacturers. The company has approximately 73 distribution warehouses located across 37 cities in 19 states and union territories, developed 424,028 square feet of warehousing space with temperature monitoring systems and modern storage solutions. Its Entero Direct platform is a cloud-based software-as-a-service solution that allows retailers to order their procurement needs from the Company.
Entero Healthcare Solutions Ltd is a IN-based company operating in Health Care Providers & Services industry. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2024-02-16. Entero Healthcare Solutions Limited is an India-based technology-driven and integrated healthcare products distribution company. The company offers a range of pharmaceuticals and other healthcare products to approximately 81,400 retail pharmacies and healthcare practitioners. Its portfolio includes 64500+ SKUs from approximately 1900 pharma companies. The company is a supplier for approximately 3,400 hospitals across India, including corporate hospital chains. The company sells private label products under its private label, Entero Surgicals. The company offers both demand generation and demand fulfilment solutions to healthcare product manufacturers. The company has approximately 73 distribution warehouses located across 37 cities in 19 states and union territories, developed 424,028 square feet of warehousing space with temperature monitoring systems and modern storage solutions. Its Entero Direct platform is a cloud-based software-as-a-service solution that allows retailers to order their procurement needs from the Company.
Strong Revenue Growth: Entero Healthcare reported Q3 revenue of INR 1,707 crores, up 26% year-on-year and 9% quarter-on-quarter, with like-for-like growth at 28.5% and organic growth at 17.1%, significantly outpacing industry growth.
Margin Improvement: Gross profit rose 29% year-on-year to INR 173 crores, with gross margin improving 30 bps to 10.1%; EBITDA margin also improved by 30 bps to 4%.
Profit Growth Impacted by One-Off: Adjusted PAT grew 36% to INR 40 crores (PAT margin 2.3%) but reported PAT grew 15% to INR 34 crores due to a one-time INR 6.1 crore labor code impact.
Working Capital & Cash Flow: Net working capital days improved to 61, and Q3 operating cash flow was INR 49 crores. Management reaffirmed guidance to deliver INR 100 crores OCF for the year.
MedTech Expansion: Recent acquisitions in MedTech are expected to boost annualized segment revenue over INR 1,000 crores and improve company gross margin by 70–90 bps and EBITDA margin by 50–75 bps post-integration.
Guidance Maintained: Management confirmed they are on track for full-year targets, including 4%+ EBITDA margin and 30% like-for-like revenue growth, with Q4 performance key to achieving these.
Acquisition Pause: Major acquisitions are complete; focus will shift to integration, margin, and cash flow improvement over the next few quarters before considering future acquisitions.
Low Effective Tax Rate: Effective tax rate remains low (~18%) due to accumulated losses, expected to rise in future as losses are utilized.
